Clinical characteristics and risk factors associated with secondary bacterial pneumonia among COVID-19 patients in ICU
The Journal of Infection in Developing Countries · 2023
DOI: 10.3855/jidc.17066 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2023. Verfasst von Insa Gül Ekiz Iscanli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Intensive Care Unit, Health Sciences University Sureyyapasa Pulmonary Disease and Pulmonary Surgery Training and Research H…. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Coinfection, COVID-19, Pneumonia, Bacterial. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
COVID-19 and secondary infections developing during COVID-19 follow-up are one of the most important causes of morbidity and mortality in intensive care units (ICU). In this study, we aimed to determine the frequency, microbiology, risk factors, and outcomes of secondary bacterial pneumonia in hospitalized patients due to COVID-19. Methodology: We studied all patients with bacterial pneumonia developed in patients with severe COVID-19 infection in the COVID-19 intensive care unit in a single-center hospital between March 16, 2020 and June 17, 2020. Patients hospitalized and followed up in the ICU for respiratory failure were examined in terms of secondary infection affecting morbidity and mortality.
Results
Ninety-six (20%) of 471 patients had secondary bacterial pneumonia, respectively; of the leading pathogens were Acinetobacter baumannii (44.8%) and Klebsiella pneumoniae (39.6%), followed by Pseudomonas aeruginosa (4.2%), Escherichia coli (3.1%), methicillin-resistant Staphylococcus aureus (MRSA) (3.1%), Streptococcus pneumoniae (3.1%), and Methicillin-susceptible Staphylococcus aureus (MSSA) (1%). The mortality rate among infected (75% / 47.5%) was significantly higher than in uninfected patients. Associated with the development of secondary bacterial pneumonia in COVID-19 patients; corticosteroid therapy [odds ratio (OR) 6250, 95% confidence interval (CI) 1.383-28.571, p = 0.017), corticosteroid dose (OR 8.862 CI 2.299-70.258, p= 0.006), duration of mechanical ventilation (OR 1.199 CI) 1.088-1.322, p< 0.001).
Conclusions
Secondary bacterial pneumonia was found to be associated with the severity and survival of the disease in patients admitted to ICU due to COVID-19. Duration of mechanical ventilation and use of corticosteroids and high-dose corticosteroids are risk factors for secondary bacterial pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Intensive Care Unit, Health Sciences University Sureyyapasa Pulmonary Disease and Pulmonary Surgery Training and Research Hospital, Istanbul, Turkey.
- Department of Infectious Disease and Clinical Microbiology, Health Sciences University Umraniye Training and Research Hospital, University of Health Science, Istanbul, Turkey.
- Department of Pulmonology, Health Sciences University Sultan Abdulhamid Han Training and Research Hospital, University of Health Science, Istanbul, Turkey.
Zitieren
APA
Ekiz Iscanli, I. G., Aydin, M., & Şaylan, B. (2023). Clinical characteristics and risk factors associated with secondary bacterial pneumonia among COVID-19 patients in ICU. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.17066
Vancouver
Ekiz Iscanli IG, Aydin M, Şaylan B. Clinical characteristics and risk factors associated with secondary bacterial pneumonia among COVID-19 patients in ICU. The Journal of Infection in Developing Countries. 2023. doi:10.3855/jidc.17066
BibTeX
@article{EkizIscanli2023,
author = {Ekiz Iscanli, Insa Gül and Aydin, Mehtap and Şaylan, Bengü},
title = {Clinical characteristics and risk factors associated with secondary bacterial pneumonia among COVID-19 patients in ICU},
journal = {The Journal of Infection in Developing Countries},
year = {2023},
doi = {10.3855/jidc.17066}
}
EUVIMED